TD Cowen Maintains Market Perform on Bristol-Myers Squibb, Lowers Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
TD Cowen analyst Steve Scala has maintained a 'Market Perform' rating on Bristol-Myers Squibb (NYSE:BMY) and lowered the price target from $80 to $66.
September 15, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
TD Cowen has maintained a 'Market Perform' rating on Bristol-Myers Squibb and lowered the price target from $80 to $66.
The lowering of the price target by TD Cowen from $80 to $66 indicates a bearish outlook for Bristol-Myers Squibb. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100